Simplex Trading’s Kezar Life Sciences KZR Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | – | Sell |
-19,900
| Closed | -$148K | – | 9846 |
|
|
2026
Q1 | $148K | Buy |
19,900
+400
| +2% | +$2.6K | ﹤0.01% | 4650 |
|
|
2025
Q4 | $123K | Buy |
+19,500
| New | +$114K | ﹤0.01% | 4772 |
|
|
2024
Q1 | – | Sell |
-1,040
| Closed | -$9K | – | 9375 |
|
|
2023
Q4 | $9K | Buy |
1,040
+10
| +1% | +$88 | ﹤0.01% | 7514 |
|
|
2023
Q3 | $12K | Buy |
1,030
+70
| +7% | +$1.24K | ﹤0.01% | 7051 |
|
|
2023
Q2 | $23K | Sell |
960
-60
| -6% | -$1.56K | ﹤0.01% | 6632 |
|
|
2023
Q1 | $31K | Sell |
1,020
-340
| -25% | -$19.7K | ﹤0.01% | 6450 |
|
|
2022
Q4 | $95K | Sell |
1,360
-25,740
| -95% | -$1.91M | ﹤0.01% | 5144 |
|
|
2022
Q3 | $2.33M | Buy |
27,100
+2,880
| +12% | +$280K | ﹤0.01% | 1820 |
|
|
2022
Q2 | $2M | Buy |
24,220
+9,150
| +61% | +$807K | ﹤0.01% | 1868 |
|
|
2022
Q1 | $2.5M | Buy |
15,070
+13,730
| +1,025% | +$1.97M | ﹤0.01% | 1875 |
|
|
2021
Q4 | $224K | Buy |
1,340
+840
| +168% | +$94.8K | ﹤0.01% | 5025 |
|
|
2021
Q3 | $27K | Hold |
500
| – | – | ﹤0.01% | 8163 |
|
|
2021
Q2 | $27K | Buy |
500
+499
| +49,900% | +$28.3K | ﹤0.01% | 8315 |
|
|
2021
Q1 | $5K | Buy |
+1
| New | +$58 | ﹤0.01% | 8209 |
|
Simplex Trading's KZR Position: Q3 2025 in Review
Simplex Trading sold out of Kezar Life Sciences (KZR) in Q3 2025, closing a stake of 43 shares.
Simplex Trading first reported a position in KZR in Q2 2020 and held it in 17 quarters. The position peaked at $259K in Q4 2021. 39 funds tracked by Wall St. Rank hold KZR as of Q3 2025.
- Simplex Trading reported no remaining Kezar Life Sciences position as of Q3 2025 after selling out during the quarter.
- Simplex Trading sold 43 Kezar Life Sciences shares in Q3 2025.
- Simplex Trading first reported a position in Kezar Life Sciences in Q2 2020 and held it in 17 quarters.
- Simplex Trading's Kezar Life Sciences position peaked at $259K in Q4 2021.
- 39 funds tracked by Wall St. Rank held Kezar Life Sciences as of Q3 2025.
Based on Simplex Trading's 13F filing for Q3 2025, filed 12 Nov 2025.